Taysha Gene Therapies, Inc. TSHA Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Taysha Gene Therapies, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Taysha Gene Therapies, Inc. (TSHA) reported increase (decrease) in contract liabilities and current deferred income of -$5.49M in Q4 2025.
- How has Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income decreased by 171.3% year-over-year, from -$2.02M to -$5.49M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a -33.7% compound annual growth rate (CAGR), from $33.56M to -$9.77M.